Notice for the Annual General Meeting of Novo Nordisk A/S
22 February 2022 - 1:05AM
Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark,
21 February
2022 – The Annual General Meeting of Novo
Nordisk A/S will be held on:
Thursday 24
March 2022 at
14.00 (CET)
The Annual General Meeting is held as a partially electronic
general meeting. Accordingly, shareholders can choose between
participating in person at Bella Center, Center Boulevard 5,
DK-2300 Copenhagen S, Denmark or participating virtually via an IT
application. We encourage shareholders to exercise their rights by
submitting proxies or votes by correspondence in advance of the
Annual General Meeting.
Also, Novo Nordisk offers the possibility of viewing the Annual
General Meeting via live webcast on Novo Nordisk’s website.
Please refer to the notice for further information. The notice
for the Annual General Meeting, including Appendix: Candidates for
the Board of Directors, is enclosed.
BOARD OF DIRECTORS All Board members elected by
the Annual General Meeting are up for election.
The Board of Directors proposes re-election of Helge Lund as
chair of the Board.
Jeppe Christiansen has decided to seek election as Board member
and consequently not to seek re-election as vice chair. The Board
proposes current member of the Board Henrik Poulsen as vice chair,
primarily because of his extensive executive and board experience
in large international companies, significant financial knowledge
and in-depth knowledge of business development, strategy,
transformation, innovation, mergers and acquisitions as well as
ESG. The nomination of Henrik Poulsen is a part of a planned
succession process in relation to the vice chair position.
The Board proposes re-election of the following Board members:
Jeppe Christiansen, Laurence Debroux, Andreas Fibig, Sylvie
Grégoire, Kasim Kutay and Martin Mackay as members of the
Board.
The Board proposes election of Christina Law as a new member of
the Board. Christina Law serves as Group CEO and member of the
boards of Raintree Group Limited, Hong Kong, China, Raintree
Investment Pte Ltd., Singapore, and La Fondation des Champions,
France, as well as member of the board of INSEAD Business School,
Singapore/France. The Board of Directors proposes election of
Christina Law primarily as she will add important perspectives to
the Novo Nordisk Board through her deep leadership experience in
Asia and other emerging markets, broad consumer sector innovation
experience, as well as extensive executive experience from several
large global companies.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin
Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph
Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Company announcement No 15/ 2022
- PR220212_AGM_notice_combined
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From May 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024